Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma
Crossref DOI link: https://doi.org/10.1007/s12094-015-1410-z
Published Online: 2015-10-28
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Estévez, L. G.
García, E.
Hidalgo, M.
Text and Data Mining valid from 2015-10-28